Following this evidence, both cardiological and endocrinological guidelines [14,15] now recommend GLP-1 RA for managing patients with both T2D and high atherosclerotic cardiovascular risk, moving from a merely glucometabolic approach to a more comprehensive strategy focusing on cardiovascular prevention in the setting of T2D. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.